Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), based in Bridgewater, New Jersey, is a global biopharmaceutical company committed to advancing health. We develop, produce, and distribute a wide-ranging portfolio of over 280 generic and specialty medicines, mainly serving the U.S. market.
Within our Affordable Medicines division, we’re actively expanding across a diverse set of complex therapeutic categories, including injectables, biosimilars, retail generics, and global markets.
Our Specialty division focuses on branded therapies, primarily targeting central nervous system and endocrine system conditions, with a growing pipeline of innovative treatments.
Through our AvKARE unit, we supply pharmaceuticals and related products to federal agencies, retail chains, and institutional clients throughout the U.S.
Amneal has evolved well beyond its origins in generics, strengthened by strategic investments that have enhanced our scientific excellence, manufacturing capabilities, and commercial reach.
We place a strong emphasis on people, with significant investments in leadership development and programs that support employee wellness and growth.
These continuous investments have enabled us to expand our product portfolio, deliver cutting-edge innovation, and enter new markets and therapeutic areas with confidence.
